Recombinant Human Serpin E2/PN1 Protein, CF
Recombinant Human Serpin E2/PN1 Protein, CF Summary
Met1-Pro397, with a C-terminal 10-His tag
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
|Formulation||Supplied as a 0.2 μm filtered solution in Sodium Acetate, NaCl and Glycerol.|
|Shipping||The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage:||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- Assay Buffer: 50 mM Tris, 10 mM CaCl2, 150 mM NaCl, 0.05% (w/v) Brij-35, pH 7.5 (TCNB)
- Recombinant Human Serpin E2/PN1(rhSerpin E2) (Catalog # 2980-PI)
- Trypsin (Sigma, Catalog # T-1426)
- Substrate: MCA-Arg-Pro-Lys-Pro-Val-Glu-NVAL-Trp-Arg-Lys(DNP)-NH2 (Catalog # ES002)
- F16 Black Maxisorp Plate (Nunc, Catalog # 475515)
- Fluorescent Plate Reader (Model: SpectraMax Gemini EM by Molecular Devices) or equivalent
- Dilute Trypsin to 0.25 μg/mL in Assay Buffer and KEEP ON ICE.
- Prepare a curve of rhSerpin E2 (MW: 43,200 Da) in Assay Buffer. Make the following serial dilutions: 250, 100, 50, 30, 20, 10, 5, 2.5, and 0.5 nM.
- Combine equal volumes of diluted Trypsin and rhSerpin E2 at each concentration of the curve. Include two controls containing equal volumes of Assay Buffer and diluted Trypsin without any rhSerpin E2.
- Incubate at room temperature for 30 minutes.
- Dilute reaction mixtures five fold in Assay Buffer.
- Dilute Substrate to 20 μM in Assay Buffer.
- Load 50 μL of the rhSerpin E2 curve in a plate, and start the reaction by adding 50 μL of 20 μM Substrate to wells.
- Read at excitation and emission wavelengths of 320 nm and 405 nm (top read), respectively, in kinetic mode for 5 minutes.
- Derive the 50% inhibition concentration (IC50) for rhSerpin E2 by plotting RFU/min (or specific activity) vs. concentration with 4-PL fitting.
- The specific activity for Trypsin at each point may be determined using the following formula (if needed):
Specific Activity (pmol/min/µg) =
|Adjusted Vmax* (RFU/min) x Conversion Factor** (pmol/RFU)|
|amount of enzyme (µg)|
*Adjusted for Substrate Blank
**Derived using calibration standard MCA-Pro-Lys-OH (Bachem, Catalog # M-1975).
- Trypsin: 0.00125 μg
- rhSerpin E2 curve: 12.5, 5, 2.5, 1.5, 1, 0.5, 0.25, 0.125, and 0.025 nM
- Substrate: 10 μM
Background: Serpin E2/PN1
Serpin E2, also known as protease nexin I or glial-derived nexin (GDN), is a member of the Serpin superfamily of the serine protease inhibitors (1). Serpin E2 is a potent inhibitor of thrombin, plasmin and plasminogen activators (2). It is differentially expressed during neuronal differentiation and is able to transform human embryonic kidney cells into neuron-like cells (3). Its over‑expression in mice leads to progressive neuronal and motor dysfunction in these animals (4). It is also over‑expressed in the majority of pancreatic carcinoma as well as gastric and colorectal cancer samples whereas it is weakly expressed in all normal pancreas and chronic pancreatitis tissue samples (5). It plays an important role in controlling male fertility because its knockout male mice show a marked impairment in fertility from the onset of sexual maturity and its abnormal expression is found in the semen of men with seminal dysfunction (6). The deduced amino acid sequence of rhSerpin E2 is the same as that in NP_001130000, which predicts Arg329 in its 397 amino acid residues (7). An alternatively splice form predicts Thr-Gly at positions 329 and 330 in its 398 amino acid sequence (8-10).
- Silverman, G.A. et al. (2001) J. Biol. Chem. 276:33293.
- Rossignol, P. et al. (2004) J. Biol. Chem. 279:10346.
- Lin, H.J. et al. (2005) Int. J. Dev. Neurosci. 23:9.
- Meins, M. et al. (2001) J. Neurosci. 21:8830.
- Buchholz, M. et al. (2003) Cancer Res. 63:4945.
- Murer, V. et al. (2001) Proc. Natl. Acad. Sci. USA 98:3029.
- Strausberg, R.L. et al. (2002) Proc. Natl. Acad. Sci. USA 99:16899.
- Sommer, J. et al. (1987) Biochemistry 26:6407.
- Gloor, S. et al. (1986) Cell 47:687.
- McGrogan, M. et al. (1988) Bio/Technology 6:172.
Citations for Recombinant Human Serpin E2/PN1 Protein, CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
Citations: Showing 1 - 8
Filter your results:
Loss of HAI-2 in mice with decreased prostasin activity leads to an early-onset intestinal failure resembling congenital tufting enteropathy
Authors: R Szabo, TH Bugge
PLoS ONE, 2018;13(4):e0194660.
ZEB1-repressed microRNAs inhibit autocrine signaling that promotes vascular mimicry of breast cancer cells
Authors: EM Langer, ND Kendsersky, CJ Daniel, GM Kuziel, C Pelz, KM Murphy, MR Capecchi, RC Sears
Sample Types: Whole Cells
The Involvement of Protease Nexin-1 (PN1) in the Pathogenesis of Intervertebral Disc (IVD) Degeneration
Sci Rep, 2016;6(0):30563.
Sample Types: Whole Cells
SERPINE2 Inhibits IL-1alpha-Induced MMP-13 Expression in Human Chondrocytes: Involvement of ERK/NF-kappaB/AP-1 Pathways.
Authors: Santoro A, Conde J, Scotece M, Abella V, Lois A, Lopez V, Pino J, Gomez R, Gomez-Reino J, Gualillo O
PLoS ONE, 2015;10(8):e0135979.
Sample Types: Whole Cells
Reduced prostasin (CAP1/PRSS8) activity eliminates HAI-1 and HAI-2 deficiency-associated developmental defects by preventing matriptase activation.
Authors: Szabo, Roman, Uzzun Sales, Katiuchi, Kosa, Peter, Shylo, Natalia, Godiksen, Sine, Hansen, Karina K, Friis, Stine, Gutkind, J Silvio, Vogel, Lotte K, Hummler, Edith, Camerer, Eric, Bugge, Thomas H
PLoS Genet, 2012;8(8):e1002937.
Sample Types: Peptide
Matriptase initiates activation of epidermal pro-kallikrein and disease onset in a mouse model of Netherton syndrome.
Authors: Sales KU, Masedunskas A, Bey AL
Nat. Genet., 2010;42(8):676-83.
Sample Types: Recombinant Protein
Prostasin expression is regulated by airway surface liquid volume and is increased in cystic fibrosis.
Authors: Myerburg MM, McKenna EE, Luke CJ, Frizzell RA, Kleyman TR, Pilewski JM
Am. J. Physiol. Lung Cell Mol. Physiol., 2008;294(5):L932-41.
Sample Types: Whole Cells
Autosomal ichthyosis with hypotrichosis syndrome displays low matriptase proteolytic activity and is phenocopied in ST14 hypomorphic mice.
Authors: List K, Currie B, Scharschmidt TC, Szabo R, Shireman J, Molinolo A, Cravatt BF, Segre J, Bugge TH
J. Biol. Chem., 2007;282(50):36714-23.
Sample Types: Cell Culture Supernates
No product specific FAQs exist for this product, however you mayView all Proteins and Enzyme FAQs
Fluorogenic Peptide Substrates
Reviews for Recombinant Human Serpin E2/PN1 Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human Serpin E2/PN1 Protein, CF and earn rewards!
Have you used Recombinant Human Serpin E2/PN1 Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image